A pilot feasibility study of gabapentin for managing pain in children with dystonic cerebral palsy.
Cerebral palsy
Dystonia
Gabapentin
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
28 08 2021
28 08 2021
Historique:
received:
03
02
2021
accepted:
20
08
2021
entrez:
29
8
2021
pubmed:
30
8
2021
medline:
14
9
2021
Statut:
epublish
Résumé
Gabapentin is often used to manage pain in children with dystonic cerebral palsy, however the evidence for its effectiveness in this population is limited. The primary objective of this feasibility pilot study was to assess the factors which might impact on a future randomised controlled trial including the ability to recruit and retain participants, assess adherence/compliance to the prescribed intervention, and ability to complete all outcome assessments. The secondary objective was to gather preliminary evidence for the effectiveness of gabapentin at reducing pain, improving comfort and reducing dystonia in children with dystonic cerebral palsy. This open label pilot study recruited children aged 5-18 years with dystonic cerebral palsy and accompanying pain affecting daily activities from four centres around Australia. Children were prescribed gabapentin for 12 weeks and were assessed at baseline, 6 weeks and 12 weeks. The primary outcome was feasibility of the protocol. Secondary outcomes were pain behaviour, pain intensity, care and comfort, individualised goal setting and dystonia severity. Thirteen children (mean age 10.4 years (SD 2.4yrs), 9 females) were recruited from 71 screened over 15 months. Two children withdrew while eight children experienced side effects. There were issues with adherence to medication dosage regimens and data collection. Improvements were seen in pain behaviour, comfort and pain related goals at 12 weeks. Dystonia was not significantly changed. Whilst gabapentin has potential to improve pain and comfort in children with dystonic CP, the feasibility of implementing a definitive randomised controlled trial is low. Alternative trials designs are required to further examine the effectiveness of gabapentin in this heterogeneous population. The trial was registered with the Australian Clinical Trial Registry ( ACTRN12616000366459 ) on 22/03/2016 and the Therapeutic Goods Administration (CT-2016-CTN-00500-1) on 22/06/2016.
Sections du résumé
BACKGROUND
Gabapentin is often used to manage pain in children with dystonic cerebral palsy, however the evidence for its effectiveness in this population is limited. The primary objective of this feasibility pilot study was to assess the factors which might impact on a future randomised controlled trial including the ability to recruit and retain participants, assess adherence/compliance to the prescribed intervention, and ability to complete all outcome assessments. The secondary objective was to gather preliminary evidence for the effectiveness of gabapentin at reducing pain, improving comfort and reducing dystonia in children with dystonic cerebral palsy.
METHODS
This open label pilot study recruited children aged 5-18 years with dystonic cerebral palsy and accompanying pain affecting daily activities from four centres around Australia. Children were prescribed gabapentin for 12 weeks and were assessed at baseline, 6 weeks and 12 weeks. The primary outcome was feasibility of the protocol. Secondary outcomes were pain behaviour, pain intensity, care and comfort, individualised goal setting and dystonia severity.
RESULTS
Thirteen children (mean age 10.4 years (SD 2.4yrs), 9 females) were recruited from 71 screened over 15 months. Two children withdrew while eight children experienced side effects. There were issues with adherence to medication dosage regimens and data collection. Improvements were seen in pain behaviour, comfort and pain related goals at 12 weeks. Dystonia was not significantly changed.
CONCLUSIONS
Whilst gabapentin has potential to improve pain and comfort in children with dystonic CP, the feasibility of implementing a definitive randomised controlled trial is low. Alternative trials designs are required to further examine the effectiveness of gabapentin in this heterogeneous population.
TRIAL REGISTRATION
The trial was registered with the Australian Clinical Trial Registry ( ACTRN12616000366459 ) on 22/03/2016 and the Therapeutic Goods Administration (CT-2016-CTN-00500-1) on 22/06/2016.
Identifiants
pubmed: 34454442
doi: 10.1186/s12887-021-02847-1
pii: 10.1186/s12887-021-02847-1
pmc: PMC8401181
doi:
Substances chimiques
Gabapentin
6CW7F3G59X
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
368Informations de copyright
© 2021. The Author(s).
Références
Pain. 2001 Aug;93(2):173-183
pubmed: 11427329
Dev Med Child Neurol. 2004 Jan;46(1):9-18
pubmed: 14974642
Dev Med Child Neurol. 1999 Jun;41(6):404-11
pubmed: 10400175
Eur J Paediatr Neurol. 2016 Jan;20(1):100-7
pubmed: 26455274
Pediatrics. 2015 Oct;136(4):e947-60
pubmed: 26416940
Dev Med Child Neurol. 2006 Mar;48(3):181-7
pubmed: 16483393
Dev Med Child Neurol. 2018 Sep;60(9):861-865
pubmed: 29882358
Dev Med Child Neurol. 2017 Aug;59(8):858-863
pubmed: 28509356
Health Qual Life Outcomes. 2003 Oct 16;1:54
pubmed: 14613568
Pediatrics. 2003 Jan;111(1):e89-97
pubmed: 12509602
Dev Med Child Neurol. 2019 Mar;61(3):305-314
pubmed: 30508221
J Paediatr Child Health. 2018 Apr;54(4):401-404
pubmed: 29105865
Pediatrics. 2013 Aug;132(2):e407-13
pubmed: 23858420
Acta Paediatr. 2010 Mar;99(3):446-51
pubmed: 20003101
Dev Med Child Neurol. 2010 May;52(5):e83-7
pubmed: 20540176
Dev Med Child Neurol. 2018 Apr;60(4):356-366
pubmed: 29405267
Dev Med Child Neurol. 2006 Oct;48(10):804-12
pubmed: 16978459
Paediatr Anaesth. 2005 May;15(5):412-20
pubmed: 15828994